Hulin Jin

Darmstadt, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study.

A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study.

Journal: Neurodegenerative disease management

Published: April 07, 2026

Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study.

Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study.

Journal: Neurology and therapy

Published: March 26, 2025

Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study.

Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study.

Journal: Therapeutic advances in neurological disorders

Published: March 13, 2025

Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study.

Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study.

Journal: Frontiers in immunology

Published: February 06, 2025

Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study.

Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study.

Journal: Frontiers in immunology

Published: October 16, 2024

Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria.

Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria.

Journal: Kidney international reports

Published: March 04, 2022

Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors.

Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors.

Journal: Investigational new drugs

Published: February 28, 2022

Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding.

Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding.

Journal: Oncoimmunology

Published: September 06, 2021

Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors.

Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors.

Journal: Investigational new drugs

Published: September 02, 2021

Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay.

Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: December 06, 2019

Showing 1-10 of 10

Last Updated: 09/26/2026